In the present study, it was demonstrated that the mRNA expression and protein secretion of MCP-1 and PAI-1 in CFs were attenuated by CNP treatment, which may serve as another mechanism that underlies the anticardiac fibrotic properties of CNP. The gene discussed is CCL2; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.